In a patient with heart failure with reduced ejection fraction (EF 25%), which medication classes have demonstrated mortality benefit?

• A. ACE inhibitors or ARBs
• B. Beta-blockers
• C. Mineralocorticoid receptor antagonists
• D. All of the above

Answer: (D)

In heart failure with reduced ejection fraction, slowing or reversing harmful neurohormonal activation and remodeling improves survival. ACE inhibitors or ARBs are foundational because they blunt the renin–angiotensin–aldosterone system, reduce afterload, prevent adverse remodeling, and have consistently shown survival benefits in major trials. Beta-blockers temper the harmful effects of chronic sympathetic stimulation on the heart, lowering arrhythmia risk and mortality; large studies with carvedilol, metoprolol succinate, and bisoprolol demonstrated clear survival advantages in HFrEF. Mineralocorticoid receptor antagonists address aldosterone-driven fibrosis and volume expansion; spironolactone and eplerenone have both reduced mortality in HFrEF populations.

Because each class independently contributes to lower mortality in this condition, the combination of these therapies has become a cornerstone of prognosis-improving treatment. So, all of the above have demonstrated mortality benefit in heart failure with reduced ejection fraction.